The law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of IntegraMed America, Inc. (NASDAQ: INMD) (“IntegraMed”) and other violations of state law by the board of directors of IntegraMed relating to the proposed buyout of the company by affiliates of the investment firm Sagard Capital Partners, L.P. (“Sagard Capital”). The firm’s investigation seeks to determine, among other things, whether the board breached its fiduciary duties by failing to maximize shareholder value. On June 11, 2012, IntegraMed announced that it had entered into a definitive agreement providing for Sagard Capital to acquire IntegraMed for approximately $169.5 million. Under the terms of the buyout transaction, IntegraMed shareholders will receive $14.05 for each share of IntegraMed common stock held. However, according to Yahoo! Finance, analysts have set a mean price target of $15.50 and at least one analyst has set a high price target of $17.00 per share. IntegraMed’s largest shareholder, who owns 26.9% of the Company’s outstanding shares, has agreed to vote in favor of the transaction. Sagard Capital owns an additional 3.7% of IntegraMed’s outstanding shares. If you currently own shares of IntegraMed and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at email@example.com, by calling (410) 415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.